West Pharmaceutical Services Inc

  • Earnings Score
  • Moat Score
  • Safety Score
  • Final Score
  • Market Cap $23.38B
  • PE 47
  • Debt $203.00M
  • Cash $490.90M
  • EV $23.09B
  • FCF $321.60M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$499.60M
EBIT$599.60M
ROE18%
ROA16%
FCF$321.60M
Equity$2.75B
Growth Stability100%
PE46.8
PEG2.79
PB8.5
P/FCF72.7
P/S8.13
Price/Cash0.02
Debt/Equity0.07
Debt/FCF0.63
Net Margins17%
Gross Margins35%
Op. Margins21%
Earnings CAGR26%
Sales Growth YoY-0%
Sales Growth QoQ6%
Sales CAGR11%
FCF CAGR26%
Equity CAGR13%
Earnings Stability0.88
Earnings Growth YoY-16%
Earnings Growth QoQ22%
Earnings CAGR 5Y17%
Sales CAGR 5Y11%
FCF CAGR 5Y10%
Equity CAGR 5Y15%
Earnings CAGR 3Y0%
Sales CAGR 3Y0%
FCF CAGR 3Y-1%
Equity CAGR 3Y6%
Market Cap$23.38B
Revenue$2.88B
Dividend Yield0%
Payout Ratio12%
Assets$3.68B
Total Debt$203.00M
Cash$490.90M
Shares Outstanding72.5M
EV23.09B
Earnings Score95%
Moat Score95%
Safety Score97%
Final Score96%
Working Capital1.03B
Current Ratio3
Gross Profit$1.00B
Shares Growth 3y-1%
Equity Growth QoQ7%
Equity Growth YoY-4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (82% of 2021 sales) and contract-manufactured products (18%). It generates 55% of its revenue from international markets and 45% from the United States.

SEC Filings

Direct access to West Pharmaceutical Services Inc (WST) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does West Pharmaceutical Services Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of West Pharmaceutical Services Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 26%
Stability 88%
loading chart...

West Pharmaceutical Services Inc Discounted Cash Flow

Fully customizable DCF calculator online for West Pharmaceutical Services Inc.

= $20B
012345678910TV
fcf$322M$406M$513M$648M$818M$1B$1.3B$1.6B$2.1B$2.6B$3.3B$33B
DCF$369M$424M$487M$559M$642M$737M$846M$971M$1.1B$1.3B$13B
Value$20B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins9%7%10%9%12%13%16%23%20%20%17%
ROA-8%12%13%13%13%15%23%20%19%16%
ROE-9%13%12%15%15%19%28%22%21%18%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-4.564.71.491.071.080.870.90.480.820.63
Debt over Equity0.380.360.210.150.140.170.140.130.080.120.07
Growth Stability---100%100%100%100%100%100%100%100%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth--2%8%6%7%7%17%32%2%2%11%
Earnings YoY growth--25%50%5%37%17%43%91%-11%1%17%
Equity YoY growth-7%9%15%9%13%18%26%15%7%15%
FCF YoY growth-14%-39%169%39%31%24%11%33%-6%10%